Lumos Pharma — Q3 2021 Earnings Presentation
9 slides from Lumos Pharma's earnings presentation, Nov 3, 2021
Slide 1: Third Quarter 2021
1 Third Quarter 2021 November 3, 2021
Slide 2: Forward Looking Statements
2 Forward Looking Statements This presentation contains forward-looking statements of Lumos Pharma, Inc. (the “Company”) that involve substantial risks and uncertainties. All such statements contained in this presentation are forward-looking statements within the meaning of The Private Securities Li
Slide 3: Agenda
3 Agenda • Lisa Miller, Senior Director of Investor Relations • Rick Hawkins, Chief Executive Officer & Chairman • Rick Hawkins, Chief Executive Officer & Chairman • John McKew, PhD, President & Chief Scientific Officer • David B. Karpf, MD, Chief Medical Officer • Lori Lawley, Chief Financial Offic
Slide 4: LUM-201 Program Pipeline
4 LUM-201 Program Pipeline Study Pre-Clinical Phase 1 Phase 2 Phase 3 Status LUM-201 (Ibutamoren) In PGHD Phase 2 Ongoing Phase 2 trial with 6-month data readout expected in second half of 2023 Long-term extension Proposed long-term extension study for OraGrowtH Trials PK/PD trial Pharmacokinetic/Ph
Slide 5: OraGrowtH210 Trial: Phase 2 Trial in PGHD
5 OraGrowtH210 Trial: Phase 2 Trial in PGHD N=20 Daily rhGH injection N=20 LUM-201: 3.2 mg/kg/day N=20 LUM-201: 1.6 mg/kg/day N=20 LUM-201: 0.8 mg/kg/day • n = 80 • PEM(+) PGHD patients • Inclusion: stim GH ≥ 5ng/ml and baseline IGF-1 > 30ng/ml • rhGH treatment naïve • ~50 trial sites US & Internati
Slide 6: OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD
6 • n = 24 • Open-label study • PGHD patients • rhGH-treatment naïve • 12-month dosing • Single, specialized clinical site • Q10 minute GH sampling for 12 hours OraGrowtH212 Trial: Pharmacokinetic / Pharmacodynamic Trial in PGHD Primary Endpoints: • Assess LUM-201 effect on endogenous GH pulsatility
Slide 7: LUM-201 Stimulates Endogenous GH Secretion vs. Exogenous rhGH Injection
7 LUM-201 Stimulates Endogenous GH Secretion vs. Exogenous rhGH Injection • LUM-201 is an oral growth hormone (GH) secretagogue • Agonist of GPCR GH Secretagogue Receptor 1a (GHSR1a) • Stimulates release of GH1 • Increases the amplitude of endogenous pulsatile GH secretion2,3 • Stimulatory effect is
Slide 8: Secure Cash Position
8 Secure Cash Position Metric Position Cash balance September 30, 2021 $100.7 million Strong financial position Cash runway through primary outcome data for OraGrowtH210 & OraGrowtH212 Trials Shares outstanding as of September 30, 2021 ~ 8.4 million Cash balance to support current operations through
Slide 9: Investment Highlights
9 Investment Highlights PGHD = Pediatric Growth Hormone Deficiency * USA, Germany, France, Italy, Spain, UK, Japan (Grandview Research, Growth Hormone Market Forecast, 2019) Late-stage Rare Disease Asset Pipeline in a Product Experienced Management Solid Financial Position • Novel oral therapeutic a